Hospital de Cruces-ko ikertzaileekin lankidetzan egindako argitalpenak (6)

2024

  1. Docetaxel Provides Oncological Benefits in the Era of New-Generation Androgen Receptor Inhibitors - or Is Three a Crowd?

    Clinical Genitourinary Cancer, Vol. 22, Núm. 1, pp. 56-66

2023

  1. Jorge clinical study: 10-year outcomes of risk-adapted radiotherapy defined by multiparametric MRI for prostate cancer

    World Journal of Urology, Vol. 41, Núm. 12, pp. 3829-3838

2022

  1. Bone health and therapeutic agents in advanced prostate cancer

    Frontiers in Bioscience - Landmark, Vol. 27, Núm. 1

2021

  1. A data mining based clinical decision support system for survival in lung cancer

    Reports of Practical Oncology and Radiotherapy, Vol. 26, Núm. 6, pp. 839-848

  2. Extreme hypofractionation with sbrt in localized prostate cancer

    Current Oncology, Vol. 28, Núm. 4, pp. 2933-2949

  3. Management of resectable stage iii-n2 non-small-cell lung cancer (Nsclc) in the age of immunotherapy

    Cancers, Vol. 13, Núm. 19